Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 614 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Function Clear all
Completed Phase 3 Interventional

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

NCT00062582
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
32
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in California, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Imaging Lung Function Using Oxygen Enhanced MRI

NCT01731015
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease
Interventions
Medical Grade Oxygen
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 23, 2026, 3:33 PM EDT
Terminated Not applicable Interventional Results available

Orthosis of Acute Traumatic Rib Fractures Via RibFx Belt for Pain Alleviation and Improved Pulmonary Function

NCT03846024
View directory record Official record
Conditions
Rib Fracture, Rib Fracture Multiple, Trauma, Trauma Chest, Trauma Injury, Trauma, Multiple
Interventions
RibFx Orthosis Belt
Device
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 23, 2026, 3:33 PM EDT
Recruiting No phase listed Observational

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

NCT00001406
View directory record Official record
Conditions
Immune System Diseases, Eosinophilia, Helminthiasis, Hypersensitivity, Parasitic Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Not applicable Interventional

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

NCT01812447
View directory record Official record
Conditions
Emphysema
Interventions
Spiration Valve System, Medical Management
Device · Other
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
40 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
32
States / cities
Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

NCT00006349
View directory record Official record
Conditions
Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions
vitamin E, donepezil hydrochloride, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Phase 3 Interventional Results available

PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers

NCT04616768
View directory record Official record
Conditions
Cancer, Lung Cancer, Gastro-intestinal
Interventions
PRO questionnaire, Step monitoring, Active nudge text feedback, PROStep Dashboard (clinicians)
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 23, 2026, 3:33 PM EDT
Terminated No phase listed Observational

Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer

NCT02117440
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Not applicable Interventional

Pulmonary Vein Isolation in Athletes

NCT03226847
View directory record Official record
Conditions
Athletes, Atrial Fibrillation, Catheter Ablation
Interventions
Pulmonary Vein Isolation
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 23, 2026, 3:33 PM EDT
Completed No phase listed Observational

Short-term Clinical Deterioration After Acute Pulmonary Embolism

NCT03915925
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
San Diego, California • Newark, Delaware • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 23, 2026, 3:33 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Pulmonary Function Using Non-invasive Forced Oscillometry

NCT03346343
View directory record Official record
Conditions
Infant, Premature, Diseases, Infant, Newborn, Diseases, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Newborn, Meconium Aspiration Syndrome, Transient Tachypnea of the Newborn
Interventions
Non-invasive forced airway oscillometry
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 2 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 3:33 PM EDT
Completed No phase listed Observational

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
25
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Phase 2 Interventional

Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

NCT04461587
View directory record Official record
Conditions
Coal Workers' Pneumoconiosis (Complicated)
Interventions
Pirfenidone
Drug
Lead sponsor
Pulmonary Research of Abingdon, LLC
Other
Eligibility
40 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Abingdon, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 23, 2026, 3:33 PM EDT
Not listed No phase listed Observational

Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS

NCT03038906
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Neuromyopathies
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Not applicable Interventional Results available

Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience

NCT03724331
View directory record Official record
Conditions
Fatigue, Self Efficacy, Quality of Life, Physical Activity, Lung Cancer, Non-Small Cell Lung Cancer
Interventions
Light Physical Activity 1, Light Physical Activity 2, Support Education Activity
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Interventions
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Drug · Combination Product
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 3:33 PM EDT
Not listed Phase 1 Interventional

Exercise for Stable Myasthenia Gravis

NCT01047761
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Exercise
Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 23, 2026, 3:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 3:33 PM EDT
Withdrawn No phase listed Observational

Transfer Impedance in Cystic Fibrosis

NCT00743158
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 23, 2026, 3:33 PM EDT
Not yet recruiting Phase 2 Interventional

Verapamil Effect in Cystic Fibrosis-related Dysglycemia

NCT07688070
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Interventions
Verapamil Hydrochloride
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, RDV Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 23, 2026, 3:33 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

NCT05892614
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 23, 2026, 3:33 PM EDT
Enrolling by invitation No phase listed Observational

Ventilator Mode and Respiratory Physiology

NCT06624254
View directory record Official record
Conditions
Pulmonary Disease, Respiratory Failure, Respiratory Effort, Breathing Mechanics
Interventions
lung mechanics, respiratory drive and effort
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 23, 2026, 3:33 PM EDT
Recruiting Phase 2 Interventional

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

NCT06992440
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
Gustavo A Heresi, MD, MS
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 3:33 PM EDT